IGFBP1 and chronic myelogenous leukemia, BCR-ABL1 positive: Using either BCR-ABL or MLL/AF9 fusion models of aggressive acute CML/AML, Ye et al found that AML cells induced high-level production of IGFBP1 from adipose tissue to decrease insulin secretion and sensitivity, and this could be targeted using an anti-IGFBP1 antibody.62